<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843622</url>
  </required_header>
  <id_info>
    <org_study_id>SM 08-01</org_study_id>
    <nct_id>NCT00843622</nct_id>
  </id_info>
  <brief_title>Controlled Study of the Ability of a Smokefree Tobacco Product to Increase the Quit Rate Among Cigarette Smokers</brief_title>
  <official_title>A Controlled Study of the Ability of a Traditional Swedish Smokeless Tobacco Product (&quot;Snus&quot;) to Increase the Quit Rate Among Cigarette Smokers Who Wish to Stop Smoking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swedish Match AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swedish Match AB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to assess if use of a low-nitrosamine, Swedish, smokefree tobacco product for
      oral use (&quot;snus&quot;) can increase the quit rate among cigarette smokers who wish to stop smoking
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a multicenter, double-blind, placebo-controlled setting, participants are randomly
      allocated to either a smokefree, oral tobacco product or a non-tobacco, non-nicotine placebo
      product with identical flavoring and physical appearance. The study consists of three phases:
      Study Product Test Period (4 weeks), Intervention Phase (12 weeks), and a Follow-Up Phase (12
      weeks). The participants are all cigarette smokers who are motivated to quit. They are
      encouraged to gradually substitute as many cigarettes as possible with study products during
      the Study Product Test Period and to refrain from all cigarettes at the latest by the first
      day of Week 5. Use of study products will continue during the 12 week Intervention Phase. The
      participants are encouraged to cut down on use of study products during the last 3 weeks to
      avoid a too abrupt ending of nicotine intake.

      All subjects are encouraged to continue in the study for clinical follow-up independent of
      smoking status although use of study products is discontinued during the Follow-Up Phase. If
      a subject has managed to quit smoking during the Intervention Phase but there is an imminent
      danger of smoking relapse during the Follow-Up Phase, that subject is informed that use of
      nicotine replacement therapy or a smokefree tobacco product is a better option in terms of
      health risks than a smoking relapse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Rate of Smoking Cessation by Self-report and Confirmed by Expired Air Carbon Monoxide Less or Equal Than 8 Ppm</measure>
    <time_frame>Week 6-28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minnesota Nicotine Withdrawal Scale</measure>
    <time_frame>Baseline, week 6, 10, 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fagerström Test for Nicotine Dependence</measure>
    <time_frame>Baseline, week 16 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers</measure>
    <time_frame>Baseline, week 6, 16, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point Prevalence Smoking Cessation</measure>
    <time_frame>6, 16, 28 weeks</time_frame>
    <description>7-day point prevalence smoking cessation verified by CO in exhaled air of 8 ppm or less</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous Smoking Cessation</measure>
    <time_frame>6-16 weeks</time_frame>
    <description>Continuous cessation according to self-report and CO in exhaled air of 8 ppm or less att all clinical visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobacco-based, smokefree product in pouch format for oral use, pouch size 1.0 or 0.5 g to be used ad libitum by participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Non-tobacco, non-nicotine placebo product in pouch format for oral use, pouch size 1.0 g or 0.5 g, to be used ad libitum by the participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-nitrosamine smokefree tobacco product for oral use</intervention_name>
    <description>Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke &gt;15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Swedish tobacco-based smokefree product for oral use (&quot;General&quot;-type Swedish &quot;snus&quot;)</other_name>
    <other_name>Placebo &quot;snus&quot; (&quot;Onico&quot;-type product)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Non-tobacco, non-nicotine placebo product</intervention_name>
    <description>Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke &gt;15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cigarette smoker who smoke more than 9 cigarettes per day (average during past month)

          -  Daily smoking more than 1 year

          -  Motivated to quit smoking using a smokefree tobacco product

          -  Good general health

        Exclusion Criteria:

          -  Use of smokefree/smokeless tobacco during past 6 months or any type of pharmaceutical
             product for smoking cessation during past 3 months

          -  Unable to refrain from nicotine replacement therapy during the study

          -  Current oral condition that could be made worse by study interventions

          -  History of clinically significant renal, hepatic, neurological, or chronic pulmonary
             disease that in the judgement of the investigator might preclude participation

          -  History of significant cardiovascular disease, including myocardial infarction, within
             the last 3 months, significant cardiac arrythmias, or poorly controlled hypertension
             that in the judgement of the investigator might preclude participation

          -  History of alcohol or substance abuse other than cigarette smoking within the past
             year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Fagerström, Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Smoker's Information Center, Hälsingborg, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Randall R Stoltz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Evansville, In</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Frank H Farmer, Jr, MD, Ph D, CPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Daytona Beach, FL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David C Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Austin, TX</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Klatt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Portland, OR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78752</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fagerstrom K, Rutqvist LE, Hughes JR. Snus as a smoking cessation aid: a randomized placebo-controlled trial. Nicotine Tob Res. 2012 Mar;14(3):306-12. doi: 10.1093/ntr/ntr214. Epub 2011 Oct 12.</citation>
    <PMID>21994343</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2009</study_first_submitted>
  <study_first_submitted_qc>February 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2009</study_first_posted>
  <results_first_submitted>May 15, 2014</results_first_submitted>
  <results_first_submitted_qc>May 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2014</results_first_posted>
  <last_update_submitted>May 15, 2014</last_update_submitted>
  <last_update_submitted_qc>May 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Smoking cessation</keyword>
  <keyword>Smokeless tobacco</keyword>
  <keyword>Snus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lobeline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from database of clinical trial volunteers, and media ads</recruitment_details>
      <pre_assignment_details>Participants were checked for eligibility prior to group assignment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Snus</title>
          <description>Tobacco-based, smokefree product</description>
        </group>
        <group group_id="P2">
          <title>Placebo Snus</title>
          <description>Non-tobacco, non-nicotine placebo product</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Snus</title>
          <description>Tobacco-based, smokefree product</description>
        </group>
        <group group_id="B2">
          <title>Placebo Snus</title>
          <description>Non-tobacco, non-nicotine placebo product</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Continuous Rate of Smoking Cessation by Self-report and Confirmed by Expired Air Carbon Monoxide Less or Equal Than 8 Ppm</title>
        <time_frame>Week 6-28</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Snus</title>
            <description>Tobacco-based, smokefree product</description>
          </group>
          <group group_id="O2">
            <title>Placebo Snus</title>
            <description>Non-tobacco, non-nicotine placebo product</description>
          </group>
        </group_list>
        <measure>
          <title>Continuous Rate of Smoking Cessation by Self-report and Confirmed by Expired Air Carbon Monoxide Less or Equal Than 8 Ppm</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minnesota Nicotine Withdrawal Scale</title>
        <time_frame>Baseline, week 6, 10, 16 and 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fagerström Test for Nicotine Dependence</title>
        <time_frame>Baseline, week 16 and 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biomarkers</title>
        <time_frame>Baseline, week 6, 16, and 28</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point Prevalence Smoking Cessation</title>
        <description>7-day point prevalence smoking cessation verified by CO in exhaled air of 8 ppm or less</description>
        <time_frame>6, 16, 28 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Continuous Smoking Cessation</title>
        <description>Continuous cessation according to self-report and CO in exhaled air of 8 ppm or less att all clinical visits</description>
        <time_frame>6-16 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Snus</title>
          <description>Tobacco-based, smokefree product</description>
        </group>
        <group group_id="E2">
          <title>Placebo Snus</title>
          <description>Non-tobacco, non-nicotine placebo product</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Standard terminology</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>severe multiple fractures in right ankle due to car accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Severe visual disturbance</sub_title>
                <description>Severe visual disturbance secondary to cerebrovascular incident</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>Standard terminology</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gingival pain, nausea, dyspepsia etc</sub_title>
                <counts group_id="E1" events="53" subjects_affected="53" subjects_at_risk="125"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Karl Fagerström</name_or_title>
      <organization>Fagerström Consulting AB</organization>
      <email>karl.fagerstrom@swipnet.se</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

